Literature DB >> 17897022

DNA topoisomerase II structures and anthracycline activity: insights into ternary complex formation.

D Dal Ben1, M Palumbo, G Zagotto, G Capranico, S Moro.   

Abstract

DNA Topoisomerase II (Top2) is an essential nuclear enzyme that regulates the topological state of the DNA, and a target of very effective anticancer drugs including anthracycline antibiotics. Even though several aspects of drug activity against Top2 are understood, the drug receptor site is not yet known. Several Top2 mutants have altered drug sensitivity and have provided information of structural features determining drug action. Here, we have revised the published crystal structures of eukaryotic and prokaryotic Top2s and relevant biochemical investigations of enzyme activity and anthracycline action. In particular, we have considered Top2 mutations conferring resistance to anthracyclines and related agents. Following a previous study (Moro et al, Biochemistry, 2004; 43: 7503-13), we have then re-built a molecular model of the entire enzyme in complex with DNA after the cleavage reaction, and used it to define the receptor site of anthracyclines. The results suggest a model wherein the drug specifically contacts the cleaved DNA as well as amino acid residues of the enzyme CAP-like domain. The findings can explain several established structure-activity relationships of antitumour anthracyclines, and provide a framework for further developments of effective Top2 poison.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17897022     DOI: 10.2174/138161207781757105

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  8 in total

1.  THE ROLE OF PROTEIN CHAPERONES IN THE SURVIVAL FROM ANTHRACYCLINE-INDUCED OXIDATIVE STRESS IN SACCHAROMYCES CEREVISIAE.

Authors:  Jana S Miles; Samantha J Sojourner; Lahcen Jaafar; Aurellia Whitmore; Selina Darling-Reed; Hernan Flores-Rozas
Journal:  Int J Adv Res (Indore)       Date:  2018-03

2.  Targeting anthracycline-resistant tumor cells with synthetic aloe-emodin glycosides.

Authors:  Elinor Breiner-Goldstein; Zoharia Evron; Michael Frenkel; Keren Cohen; Keren Nir Meiron; Dan Peer; Yael Roichman; Eliezer Flescher; Micha Fridman
Journal:  ACS Med Chem Lett       Date:  2011-05-12       Impact factor: 4.345

3.  New doxorubicin nanocarriers based on cyclodextrins.

Authors:  Maurizio Viale; Valentina Giglio; Massimiliano Monticone; Irena Maric; Giovanni Lentini; Mattia Rocco; Graziella Vecchio
Journal:  Invest New Drugs       Date:  2017-04-04       Impact factor: 3.850

4.  The effects of anthracycline drugs on the conformational distribution of mouse P-glycoprotein explains their transport rate differences.

Authors:  P H Nguyen; K P Sigdel; K G Schaefer; G A K Mensah; G M King; A G Roberts
Journal:  Biochem Pharmacol       Date:  2020-01-16       Impact factor: 5.858

5.  Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway.

Authors:  Ying Pang; Chunzhang Yang; Jan Schovanek; Herui Wang; Petra Bullova; Veronika Caisova; Garima Gupta; Katherine I Wolf; Gregg L Semenza; Zhengping Zhuang; Karel Pacak
Journal:  Oncotarget       Date:  2017-04-04

6.  1-Amino-4-hydroxy-9,10-anthraquinone - An analogue of anthracycline anticancer drugs, interacts with DNA and induces apoptosis in human MDA-MB-231 breast adinocarcinoma cells: Evaluation of structure-activity relationship using computational, spectroscopic and biochemical studies.

Authors:  Palash Mondal; Sanjay Roy; Gayathri Loganathan; Bitapi Mandal; Dhanasekaran Dharumadurai; Mohammad A Akbarsha; Partha Sarathi Sengupta; Shouvik Chattopadhyay; Partha Sarathi Guin
Journal:  Biochem Biophys Rep       Date:  2015-10-23

7.  Cardiotoxicity After Anthracycline Treatment in Survivors of Adult Cancers: Monitoring by USCOM, Echocardiography and Serum Biomarkers.

Authors:  Alessandro Pastore; Sandra Geiger; Dorothee Baur; Andreas Hausmann; Johanna Tischer; Sophia Horster; Hans Joachim Stemmler
Journal:  World J Oncol       Date:  2013-03-06

8.  Selective inhibition of yeast regulons by daunorubicin: a transcriptome-wide analysis.

Authors:  Marta Rojas; Marta Casado; José Portugal; Benjamin Piña
Journal:  BMC Genomics       Date:  2008-07-30       Impact factor: 3.969

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.